Clinical Trial Search

Primary: Change From Baseline in Brain PCr/ATP Ratio as Measured by Phosphorus Magnetic Spectroscopy (31P-MRS) After 10 Months of Metformin Administration — -0.045; -0.016…

Primary: Ex Vivo Cytokine Response of Peripheral Blood Mononucleocytes (PBMC) to Inflammatory Stimuli Compared to Baseline, Throughout Exposure, and Following Exposure to…

Primary: Heart Rate Variability (Time Domain) — 0.92; 0.83 msec/msec — p=0.77

Primary: Treatment Satisfaction as Measured by the Treatment Satisfaction Questionnaire for Medication (TSQM II) — 39.42; 51.92 score on a scale

Primary: Weight Gain — 2.54; 5.88 kilogram

Primary: Mood Following 24h of Smoking Abstinence — 36.5; 33.8; 37.9; 14.3 score on a scale

Primary: Serum Levels of Metformin at Different Time Points — 4.36; 4.25; 5.09; 7.42 µM

Primary: Change in Weight From Baseline at 12 Months or More — -8.37 Kg — p=<0.05

Primary: Change is Leptin to Adiponectin Ratio (LAR) — 2.2; 1.3; 1.3; 1.4 ng/micrograms

Primary: Change in Activated S6serine235 (i.e., the Ratio of pS6serine235/S6serine235) — 0.0228 weighted ratio of staining cells — p=> 0.773

Primary: Change in Total Recall Score in the Selective Reminding Test — 5.7; 9.4 score on a scale — p=0.05

Primary: Fundus Autofluorescence Imaging to Measure the Rate of Change in Area of Geographic Atrophy — 0.41; 0.35 mm/year — p=0.39

Primary: Cmax (Maximum Observed Concentration of Drug Substance in Plasma) — 875.86; 886.39 ng/mL

Primary: Maximum Observed Concentration (Cmax) — 884.297; 963.384; 942.653 Nanograms per milliliter (ng/mL) — p=0.1413

Primary: Birth Weight Per Arm — 3604; 3589 g

Primary: Mean Prostate Specific Antigen (PSA) Level — 0.61; 0.70; 0.54 ng/mL

Primary: Change in Hemoglobin A1c From Baseline to 26 Weeks, Adjusted for Baseline Hemoglobin A1c. — 9.0; 8.9; 0.2; 0.2 percentage

Primary: Hepatic Fatty Acid Oxidation — 0.052; 0.045; 0.042 micromol/ml/min

Primary: Frailty Index Based on Deficit Accumulation — -0.0002; 0.0002 Index score

Primary: Invasive Disease-free Survival in Hormone Receptor (ER and PgR) Positive Sub-groups — 86.5; 85.9 percentage of patients without event — p=0.93

Primary: Health-Related Quality of Life (HRQoL) — 56; 53 score on a scale

Primary: Improvement in Left Ventricular Ejection Fraction — 53.1; 54.8 % of LVEF

Primary: Maximum Drug Concentration of Metformin in Plasma After Single Dose Administration (Cmax) — 1550; 1460 microgram per liter (mcg/L)

Primary: AUC (0-t) of Plasma Metformin — 5362; 10411; 8705; 11788 ng*h/mL — p=0.0011

Primary: Metformin AUC — 59.6; 54.5; 57.3 mcg*hr/mL

Primary: Safety and Tolerability of Metformin — 50; 100; 82; 100 percentage of participants

Primary: Area-Under-the-Curve (AUC) of Pravastatin After Metformin — 264.2; 170.5 ng/ml × h — p=0.02

Primary: Cmax (Maximum Observed Concentration of Drug Substance in Plasma) — 853.63; 824.89 ng/mL

Primary: Mitochondrial Function — 7.1; 43.2; 15.6; 13.8 percent change in pmol/s/mg tissue

Primary: Change From Baseline in Hemoglobin A1C (A1C) at Week 24 — -0.67; -0.02 Percent — p=<0.001